GleamWall
中文EN

ESLA Estrella Immunopharma, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1844417 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.7%
TTM EPS YoY20.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-484.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets936.1%
Debt / equity—
Current ratio0.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.70x
Accruals ratio-143.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$6.90M$1.40M$1.40M$25,414$4.15M$4.66M$1.41M$32,566
SG&A expense$595,827$684,015$891,789$587,785$581,468$883,727$694,110$1.02M
Operating income-$7.50M-$2.08M-$2.29M-$613,199-$4.73M-$5.54M-$2.10M-$1.05M
Pretax income-$7.38M-$2.31M-$2.29M-$613,199-$4.80M-$5.54M-$2.10M-$1.05M
Income tax———-$25$0$850$13—
Net income-$7.38M-$2.31M-$2.29M-$613,174-$4.80M-$5.54M-$2.10M-$1.05M
EPS (basic)-0.17-0.05-0.05—-0.13-0.15-0.06—
EPS (diluted)-0.17-0.05-0.05—-0.13-0.15-0.06—
Weighted avg. shares (diluted)43.59M43.00M42.12M—37.10M36.17M36.19M—
Banking
Deposits$1.50M$1.50M$1.50M$1.50M$1.50M$1.50M$1.50M$1.50M
Balance sheet
Cash & equivalents$100,000$100,000$1.93M$1.38M$1.63M$1.32M$421,473$916,916
Current assets$1.67M$1.82M$2.16M$1.68M$2.02M$1.48M$944,268$1.64M
Total assets$1.67M$1.82M$3.66M$3.18M$3.52M$2.98M$2.44M$3.14M
Current liabilities$15.64M$9.26M$8.93M$13.54M$13.36M$9.08M$4.28M$3.00M
Total liabilities$15.64M$9.26M$8.93M$13.54M$13.36M$9.08M$4.28M$3.00M
Shareholders' equity-$13.97M-$7.43M-$5.27M-$10.37M-$9.84M-$6.09M-$1.83M$143,731
Shares outstanding43.97M——37.97M37.77M37.07M36.17M36.19M
Cash flow statement
Operating cash flow-$217,212-$1.78M-$6.70M-$177,487-$727,332-$414,879-$465,981-$896,066
Financing cash flow$163,000$4$7.24M-$64,821$1.04M$1.31M-$29,462$15,479
Stock-based compensation$105,628$145,298$146,714$148,360$152,421$159,098$159,095$432,256

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.